| METHOTREXATE | None | ||
| 10MG/0.4ML, 15MG/0.6ML, 17.5MG/0.7ML, 20MG/0.8ML, 22.5MG/0.9ML, 25MG/1ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| Otrexup PFS is a folate analog metabolic inhibitor indicated for the: • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy. • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy. | |||
|
Yes
| |||
| OTREXUP PFS | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||
| ********* ******* *** ******** | ********* ***** ********* ****** | ********* ******* *** ******** | ********* ***** ********* ****** | ******** ****** ****** | ********* ***** ********* ****** | ********* ***** ********* ****** | ********* ******* *** ******** | ********* ******* *** ******** | ******** ****** ****** | ******** ****** ****** | ********* ******* ******** | ********* ***** ********* ****** | ******** ****** ****** | ********* ***** ********* ****** | ****** ******** *** ******** | ****** ******** *** ******** | ****** ******** *** ******** | ****** ******** *** ******** | ****** ******** *** ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|